The present invention relates to a novel composition for treating a gastroesophageal disease. A liquid composition for oral administration, according to the present invention, is advantageous in being convenient for the patient to consume due to low viscosity, in having a simple manufacturing process, and in being easy to sterilize, and effectively treats the gastroesophageal disease by forming a floating gel that has superior structural strength.
The present invention provides a mixed extract containing a Pharbitidis semen extract and a Corydalis tuber extract in a weight ratio of 1:5, a pharmaceutical composition for the prevention or treatment of gastrointestinal motility disorders, including the same and a health functional food including the same. The mixed extract improves gastric emptying, gastric accommodation and gastrointestinal transit, accelerates gastrointestinal motility, and inhibits visceral hypersensitivity to effectively prevent or treat gastrointestinal motility disorders.
A61K 36/39 - Convolvulaceae (famille de la belle-de-jour), p. ex. liseron
A61K 36/50 - Fumariaceae (famille du fumeterre), p. ex. cœur de Marie
A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p. ex. antiacides, antisécrétoires, protecteurs de la muqueuse
A23L 1/29 - Modification de la qualité nutritive des aliments; Produits diététiques ( A23L 1/09 a priorité;substituts diététiques du sel A23L 1/22)
The present invention relates to a pharmaceutical composition containing a quinoline derivative, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof. The pharmaceutical composition improves gastric emptying rate, gastric accommodation, gastrointestinal transit and the like, and can stimulate gastrointestinal motility to effectively prevent or treat gastrointestinal motility disorders and diseases.
A61K 31/4738 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques
A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p. ex. antiacides, antisécrétoires, protecteurs de la muqueuse
A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
4.
HEMIOXALATE SALT OF CRYSTALLINE O-DESMETHYLVENLAFAXINE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION THEREOF
The present invention relates to hemioxalate of crystalline O-desmethylvenlafaxine which maximizes solubility and has physicochemical properties of a solid material which is pharmaceutically preferable due to its non-hygroscopicity, to a preparation method of the hemioxalate, and to a pharmaceutical composition of the hemioxalate. The hemioxalate of crystalline O-desmethylvenlafaxine according to the present invention can: increase bioavailability of drugs due to its high solubility; allow various formulations to be very easily designed without composition size limitations; and administer high doses of drugs regardless of the dose-limiting volume of an animal. Thus, the hemioxalate of crystalline O-desmethylvenlafaxine facilitates the confirmation of expressible toxicity, and is suitable for distribution of raw materials and production of medicines because of low hygroscopicity.
C07C 215/64 - Composés contenant des groupes amino et hydroxy liés au même squelette carboné ayant des groupes hydroxy liés à des atomes de carbone d'au moins un cycle aromatique à six chaînons et des groupes amino liés à des atomes de carbone acycliques ou à des atomes de carbone de cycles autres que des cycles aromatiques à six chaînons du même squelette carboné avec des cycles autres que des cycles aromatiques à six chaînons, faisant partie du squelette carboné
The present invention provides a novel benzamide derivative or a pharmaceutically acceptable salt thereof, a method for preparing the same, and a 5-HT4 receptor agonist containing the same as an active ingredient. Benzamide derivatives of the present invention have a superior affinity for 5-HT4 receptors, a capability to reduce a gastric emptying time and a low toxicity, and consequently are therapeutically effective for the treatment of a variety of diseases associated with 5-HT4 receptors.
C07D 211/16 - Composés hétérocycliques contenant des cycles pyridiques hydrogénés, non condensés avec d'autres cycles avec uniquement des atomes d'hydrogène et de carbone liés directement à l'atome d'azote du cycle ne comportant pas de liaison double entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés directement aux atomes de carbone du cycle avec des radicaux ne contenant que des atomes de carbone et d'hydrogène liés aux atomes de carbone du cycle l'atome d'azote du cycle étant acylé
C07D 211/26 - Composés hétérocycliques contenant des cycles pyridiques hydrogénés, non condensés avec d'autres cycles avec uniquement des atomes d'hydrogène et de carbone liés directement à l'atome d'azote du cycle ne comportant pas de liaison double entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés directement aux atomes de carbone du cycle avec des radicaux hydrocarbonés substitués liés aux atomes de carbone du cycle avec des radicaux hydrocarbonés, substitués par des atomes d'azote
A61K 31/435 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle
This invention relates to a novel compound represented by the following Chemical Formula 1, a process for preparing it, and its pharmaceutically approved salt comprising it as an active ingredient. The compound of this invention is GLP 1 receptor regulating low molecular weight compound useful for treatment of metabolic diseases such as diabetes and obesity by regulating the function of glucagon like peptide 1 receptor (GLP 1 receptor) for the disease or disorder carried by GLP 1 since it has the effects on a drop of blood sugar and an improvement of insulin resistance.
C07D 417/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
C07D 403/12 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
A61K 31/498 - Pyrazines ou pipérazines condensées en ortho ou en péri avec des systèmes carbocycliques, p. ex. quinoxaline, phénazine
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR THE TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE AND THE METHOD FOR PREVENTION OR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE USING THE SAME
The present invention provides a pharmaceutical composition for the prevention and treatment of a non-alcoholic fatty liver disease (NAFLD), containing an active ingredient selected from the group consisting of Compound 1 represented by formula 1, sitagliptin, vildagliptin, linagliptin or a pharmaceutically acceptable salt thereof. Further, the present invention provides a method for the prevention or treatment of a non-alcoholic fatty liver disease, including administering an effective amount of an active ingredient selected from the group consisting of Compound 1 represented by formula 1, sitagliptin, vildagliptin, linagliptin or a pharmaceutically acceptable salt thereof to a mammal including a human in need thereof. Further, the present invention provides use of Compound 1 represented by formula 1, sitagliptin, vildagliptin, linagliptin or a pharmaceutically acceptable salt thereof, for manufacturing a pharmaceutical composition for the prevention or treatment of a non-alcoholic fatty liver disease.
A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine
A61K 31/401 - ProlineSes dérivés, p. ex. captopril
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
The present invention relates to the crystal form of Epirubicin hydrochloride stable against heat and water and the preparation method thereof. The novel crystal form has the physiochemical property stable against heat and water according to the present invention and it improves the excellent stability of the agents by preventing the relative substances from the one containing it. Furthermore, the crystal form of Epirubicin hydrochloride is suitable for mass production since it is easily prepared.
The present invention provides a pharmaceutical composition for the prevention or treatment of obesity or a lipid-related metabolic disease and a food for the amelioration or prevention of obesity or a lipid-related metabolic disease, containing an extract of at least one xylem selected from Thuja orientalis Linne xylem, Juniperus mexicana xylem and Thujopsis dolabrata xylem or (-)-thujopsene, as an active ingredient. The extract and (-)-thujopsene contained in the composition or food of the present invention exhibit significant body fat- and body weight-reducing effects and lowers plasma levels of glucose, GOT, GPT, LDL-cholesterol, and LDL/VLDL cholesterol. Accordingly, the composition and food of the present invention are effective for the treatment, amelioration or prevention of lipid-related metabolic diseases or obesity.
Provided is a pharmaceutical composition comprising a bisphosphonate having an osteoporosis treating effect, a pH-sensitive macromolecular substance, a foaming agent and a buffering agent. The composition of the present invention imposes no obligatory requirement to take a large amount of water when it is taken, and also has a buffering ability sufficient to keep the pH in the stomach at or above 3.5 after taking, and thus it prevents oesophageal irritation due to gastric reflux and so entails no need to maintain a particular standing posture. Also, even if the pH inside the stomach falls below 3.5 in that portion of patients whose stomach acidity is excessively low, oesophageal irritation due to gastric reflux can be prevented by forming a floating and swelling type of RAFT, and there is a dramatic improvement in convenience of drug taking for patients who take bisphosphonate drugs over the longer term, and there is a foaming effect which extends across two stages.
The present invention relates to a process for preparing clopidogrel hydrogensulfate Form I having a large particle size and containing 0.1% or less impurities, and clopidogrel hydrogensulfate Form I produced thereby. The process of the present invention allows a clopidogrel hydrogensulfate Form I to have a pharmaceutically useful particle size and an even spherical form, and to contain 0.1% or less of impurities.
C07D 495/02 - Composés hétérocycliques contenant dans le système condensé au moins un hétérocycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle dans lesquels le système condensé contient deux hétérocycles
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
The present invention relates to a donepezil resin complex consisting of donepezil or pharmaceutically acceptable salts thereof and a cation-exchange resin, and to oral preparations containing same. The complex of the present invention is advantageous in that it can effectively mask the unpleasant taste of donepezil or of the salts thereof, and therefore can be formulated into a variety of dosage forms such as a tablet, an orally disintegrating tablet, a troche tablet, a suspension, etc.
C07D 211/22 - Composés hétérocycliques contenant des cycles pyridiques hydrogénés, non condensés avec d'autres cycles avec uniquement des atomes d'hydrogène et de carbone liés directement à l'atome d'azote du cycle ne comportant pas de liaison double entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés directement aux atomes de carbone du cycle avec des radicaux hydrocarbonés substitués liés aux atomes de carbone du cycle avec des radicaux hydrocarbonés, substitués par des atomes d'oxygène ou de soufre liés par des liaisons simples par des atomes d'oxygène
C07D 211/32 - Composés hétérocycliques contenant des cycles pyridiques hydrogénés, non condensés avec d'autres cycles avec uniquement des atomes d'hydrogène et de carbone liés directement à l'atome d'azote du cycle ne comportant pas de liaison double entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés directement aux atomes de carbone du cycle avec des radicaux hydrocarbonés substitués liés aux atomes de carbone du cycle avec des radicaux hydrocarbonés, substitués par des atomes d'oxygène ou de soufre liés par des liaisons doubles ou par deux atomes d'oxygène ou de soufre, liés au même atome de carbone par des liaisons simples par des atomes d'oxygène
The present invention provides an acid addition salt of Udenafil, a preparation method thereof and a pharmaceutical composition comprising the same. The acid addition salt of Udenafil in which Udenafil is bonded to an organic acid selected from the group consisting of oxalic acid, benzenesulfonic acid, camphorsulfonic acid, cinnamic acid, adipic acid and cyclamic acid, has excellent solubility in an aqueous medium, water stability and crystallinity, thereby being suitably applied for a pharmaceutical composition.
C07D 487/02 - Composés hétérocycliques contenant des atomes d'azote comme uniques hétéro-atomes dans le système condensé, non prévus par les groupes dans lesquels le système condensé contient deux hétérocycles
14.
CONTROLLED-RELEASE COMPOSITION FOR PRODUCING SUSTAINED-RELEASE PREPARATION CONTAINING UDENAFIL
The present invention relates to a controlled-release composition for producing a sustained-release preparation containing udenafil. More particularly, the present invention relates to a controlled-release composition for producing a sustained-release preparation containing udenafil, said composition comprising (A) udenafil and a pharmaceutically acceptable salt, (B) a solubility modulator, (C) an adsorbent, and (D) a hydrophilic polymer. The controlled-release composition for producing a sustained-release preparation containing udenafil according to the present invention releases drugs constantly regardless of the pH level in the gastrointestinal tract, and thus freely controls the drug release time within the range of 3 to 24 hours, and reduces the variability in the effect of drugs among individuals. In addition, the composition of the present invention can be produced into a sustained-release preparation which has an optimum condition for expressing the effect of drugs in the treatment of diseases such as pulmonary arterial hypertension, hepatic portal vein hypertension, benign prostatic hyperplasia, and the like, which can be treated by udenafil and which requires the administration of drugs over a long period of time. Further, the composition of the present invention can control the release of drugs in accordance with the time taken for the absorption thereof when said drugs are applied to a living body, and thus can be valuably used in preventing and treating erectile dysfunction.
A61K 47/48 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. supports, additifs inertes l'ingrédient non actif étant chimiquement lié à l'ingrédient actif, p.ex. conjugués polymère-médicament
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 9/22 - Pilules, pastilles ou comprimés du type à libération prolongée ou discontinue
The present invention relates to a method for producing taxane derivatives with anticancer activity. The method of the present invention produces taxane derivatives in a short time under mild conditions by employing phenyl oxazinan dione compounds which are novel compounds, as a reactant, such that the phenyl oxazinan dione compounds react to baccatin III derivatives.
C07D 305/14 - Composés hétérocycliques contenant des cycles à quatre chaînons comportant un atome d'oxygène comme unique hétéro-atome du cycle condensés avec des carbocycles ou avec des systèmes carbocycliques
16.
NOVEL BENZAMIDE DERIVATIVE COMPOUND, AND A METHOD FOR PRODUCING SAME
The present invention relates to a compound of the following chemical Formula I, isomers thereof or pharmaceutically acceptable salts of the compound and their isomers; to a production method for the compound and isomers thereof and to a pharmaceutical composition which is efficacious on 5-HT4 receptors and which contains the compound or an isomer thereof as an active principle.
C07D 403/04 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
17.
FAST-DISSOLVING AMLODIPINE TABLETS OF IMPROVED STABILITY AND A METHOD OF MANUFACTURE THEREOF
The present invention relates to a method for manufacturing fast-dissolving amlodipine tablets having improved storage stability as a result of containing amlodipine or a pharmaceutically acceptable salt and having physicochemical stability. Fast-dissolving amlodipine tablets manufactured according to the present invention exhibit excellent results when evaluated in terms of appearance, content and impurities, and therefore have sufficient storage stability up to their expiration date, despite amlodipine's characteristic physicochemical instability in the presence of moisture. Said amlodipine tablets dissolve quickly in the mouth with no discomfort.
The present invention relates to a liquid pharmaceutical composition for injection containing docetaxel. The composition of the present invention contains (A) docetaxel and a pharmaceutically acceptable salt, (B) a surface active agent selected from polysorbate, polyoxyethylene glycol ester and polyoxyethylene castor oil derivatives, (C) a solvent containing anhydrous ethanol in the range of concentration of 100 to 800mg/ml in an injection solution, and (D) a pH adjuster of the amount suitable for adjusting pH of the liquid composition to 5 or lower. The composition of the present invention can be directly diluted in a perfusion liquid even without using an intermediary dilute solution in cases where the composition of the present invention is used as injectable preparations as the composition is formed into a single liquid phase. Further, the composition of the present invention is suitable for effective injection of docetaxel as the pharmaceutical stability of the composition is significantly improved.
A61K 31/337 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à quatre chaînons, p. ex. taxol
A61K 47/08 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant de l'oxygène
There are provided intermediates used to prepare a derivative, (3R,5R)-7-[2-(4-fluorphenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-lH-pyrrol-l-yl]-3,5-di hydroxyheptanoic acid, which has an effect to suppress cholesterol in blood, and a process for preparing pyrrolylheptanoic acid derivatives therefrom. In accordance with the present invention, the 5-(4-fluorphenyl)-2-isopropyl-4-phenyl-lH-pyrrole-3-carbonyl derivative is provided as one of the novel synthetic intermediates that are used to prepare pyrrolylheptanoic acid derivatives including a derivative, (3R,5R)-7-[2-(4-fluorphenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-lH-pyrrol-l-yl]-3,5-di hydroxyheptanoic acid. Therefore, the (3R,5R)-7-[2-(4-fluorphenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-lH-pyrrol-l-yl]-3,5-di hydroxyheptanoic acid derivative may be prepared from the carbonyl derivative in a high yield for a short time period under a moderate condition.
C07D 207/34 - Composés hétérocycliques contenant des cycles à cinq chaînons, non condensés avec d'autres cycles, ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle avec uniquement des atomes d'hydrogène ou de carbone liés directement à l'atome d'azote du cycle comportant deux liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des hétéro-atomes ou avec des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile, liés directement aux atomes de carbone du cycle
The present invention relates to a composition and a method for treating or preventing benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS) without showing the side effect, by dramatically relaxing the smooth muscle in prostate and bladder.
There is provided a pharmaceutical composition comprising an extract of Artermisia sp. (Artemisia asiatica, A. mongolica, A. princeps, A. argyi) using a gastro-retentive drug delivery system (GRDDS), and an oral sustained-release formulation using the same. The oral sustained-release formulation comprising an Artemisia extract according to one exemplary embodiment of the present invention may be useful to enhance an absorption rate of a drug in the gastrointestines by allowing the drug to maintain a floating state in the digestive juice or body fluid when the oral sustained-release formulation is administered into a human body, and to improve a therapeutic effect of the drug by slowly releasing the drug to increase a topical reaction of Artermisia asiatica Nakai while retaining the drug in the stomach and intestines for an extended time.
A61K 9/32 - Revêtements organiques contenant des polymères synthétiques solides
A61K 9/28 - DragéesPilules ou comprimés avec revêtements
A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres
A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p. ex. antiacides, antisécrétoires, protecteurs de la muqueuse
22.
FORMULATION FOR INHALATION COMPRISING FIBROBLAST GROWTH FACTOR-2 AS AN EFFECTIVE INGREDIENT FOR TREATMENT OR PREVENTION OF ASTHMA AND/OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE
A technology for treatment or prevention of asthma and chronic obstructive pulmonary disease (COPD) by inhalation administration of FGF-2 (Fibroblast Growth Factor-2) or bFGF (basic Fibroblast Growth Factor) to patients in need of treatment or prevention of asthma or COPD, wherein the FGF-2 is administered by inhalation at a daily dose of 0.015 to 600ng based on 60kg body weight, is provided. In an embodiment of the present invention, inhalation administration of FGF-2 for the treatment and/or prevention of asthma and COPD, even when administered at a low dose, not only exhibits at least the same level of efficacy as the case of intravenous and hypodermic injections, but is also able to minimize toxicity and side effects.
There is provided a gastroretentive system matrix formulation containing a compound represented by Formula 1 that has a therapeutic effect on gastritis and is solubilized in the stomach, and a method for preparing the gastroretentive system matrix formulation. The gastroretentive system matrix formulation according to the present invention may be useful to improve the solubility of a solubilized drug under an acidic condition in the stomach, and maximize an anti-inflammatory effect of the solubilized drug by increasing the retention time of the formulation in the stomach through the continuous release the solubilized drug into the stomach.
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
24.
INJECTABLE READY TO USE SOLUTIONS COMPRISING HUMAN CHORIONIC GONADOTROPIN
There is provided an injectable ready-to-use solution comprising human chorionic gonadotropin (hCG) capable of stably storing hCG. The injectable ready-to-use solution comprising human chorionic gonadotropin (hCG) according to the present invention may be useful to stably store hCG without reconstitution from a freeze-dried materials since the injectable ready-to-use solution comprises pharmaceutical non-reducing sugars such as trehalose and methionine.
The present invention provides a 3',4',5-trimethoxy flavone derivative and a pharmaceutically acceptable salt thereof, preparation thereof, and a pharmaceutical composition for the treatment and prevention of dry eye syndrome comprising the same as an active ingredient. The 3',4',5-trimethoxy flavone derivative and its pharmaceutically acceptable salt inhibit corneal damage through excellent stimulatory action on mucus secretion in the conjunctiva and therefore may be effective as a prophylactic or therapeutic agent for dry eye syndrome.
C07D 311/30 - Benzo [b] pyrannes non hydrogénés dans le carbocycle avec des atomes d'oxygène ou de soufre liés directement en position 4 avec des cycles aromatiques liés en position 2 ou 3 avec des cycles aromatiques liés uniquement en position 2 non hydrogénés dans l'hétérocycle, p. ex. flavones
26.
DPP-IV INHIBITOR INCLUDING BETA-AMINO GROUP, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR PREVENTING AND TREATING A DIABETES OR AN OBESITY
The present invention provides a novel heterocyclic compound containing a beta-amino group, a method for preparing the same, and a pharmaceutical composition comprising the same heterocyclic compound or a pharmaceutically acceptable salt thereof as an active ingredient. The heterocyclic compound of the present invention exhibits excellent DPP-IV inhibitory activity and bioavailability and therefore can be useful for the prophylaxis or treatment of DPP-IV-related diseases such as diabetes or obesity.
C07D 241/08 - Composés hétérocycliques contenant des cycles diazine-1,4 ou diazine-1,4 hydrogéné non condensés avec d'autres cycles comportant une ou deux liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des atomes d'oxygène liés directement aux atomes de carbone du cycle
The present invention provides a novel benzamide derivative represented by formula 1 and an isomer, a pharmaceutically acceptable salt or hydrate thereof, and a composition for activating a 5-HT4 receptor comprising the same, as an active ingredient. Benzamide derivatives of the present invention has superior affinity for 5-HT4 receptors, capability to reduce the gastric evacuation time, capability to alleviate ventricular tachycardia, ventricular fibrillation, torsades de pointes and QT prolongation, and low toxicity. Therefore, benzamide derivatives of the present invention are therapeutically effective for digestive system diseases.
C07D 211/62 - Atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile liés en position 4
C07D 401/06 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 417/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
A61K 31/165 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide
A61K 31/445 - Pipéridines non condensées, p. ex. pipérocaïne
A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
A61P 1/06 - Antispasmodiques, p. ex. médicaments pour le traitement des coliques, des dyskinésies œsophagiennes
28.
NOVEL CRYSTAL FORMS OF PYRROLYLHEPTANOIC ACID DERIVATIVES
The present invention provides novel crystalline forms D1 and D2 of [R-(R*,R* )]-2-(4- fluorophenyl)-β,δ-dihydroxy-5-(l-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H- pyrrole- 1-heptanoic acid hemicalcium salt, and hydrates thereof. The crystalline forms D1 and D2 have X-ray powder diffraction peaks described in Figs. 1 and 3, respectively. Further, the present invention provides processes for preparing the crystalline forms and pharmaceutical compositions comprising the crystalline forms. The crystalline forms can be produced on a commercial scale and exhibit excellent stability.
C07D 207/34 - Composés hétérocycliques contenant des cycles à cinq chaînons, non condensés avec d'autres cycles, ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle avec uniquement des atomes d'hydrogène ou de carbone liés directement à l'atome d'azote du cycle comportant deux liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des hétéro-atomes ou avec des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile, liés directement aux atomes de carbone du cycle
NOVEL PHENYLPROPIONIC ACID DERIVATIVES AS PEROXISOME PROLIFERATOR-ACTIVATED GAMMA RECEPTOR MODULATORS, METHOD OF THE SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
The present invention provides a novel phenylpropionic acid derivative and a PPAR-γ modulator comprising the same as an active ingredient. The phenylpropionic acid derivative of the present invention has modulatory action on function of PPAR-γ and then exhibits hypoglycemic, hypolipidemic and insulin resistance-reducing effects on PPAR-mediated diseases or disorders. Therefore, the present invention is prophylactically or therapeutically effective for diabetes and metabolic diseases.
The present invention relates to three-branched PEG-G-CSF conjugate of general formula (1 ) in which the bonding ratio of three-branched polyethylene glycol(PEG) and G-CSF is 1 : 1 (mol/mol), wherein PEG has an average molecular weight of from 200 to 45.000 daltons; a pharmaceutical composition comprising the same, and a preparing method thereof.
Disclosed is an agent for preventing and treating diabetic peripheral neuropathy including a granulocyte colony stimulating factor (G-CSF) as an active ingredient, which is able to improve nerve conduction velocity and pain sensitivity by regenerating blood vessels in peripheral tissues and rehabilitating damaged nerve tissues.
The present invention relates to three-branched polyethylene glycol-interferon alpha conjugate of general formula (1) wherein polyethylene glycol has an average molecular weight of from 400 to 45,000 daltons, and a pharmaceutical composition comprising the same. The bioactive polyethylene glycol-interferon alpha conjugate of general formula (1) has antiviral and antitumoral activities, improved yield and purity by high reactivity in the reaction, and the effects to increase the half-life in blood remarkably, and to minimize the decreases in biological activity of interferon.
A61K 47/48 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. supports, additifs inertes l'ingrédient non actif étant chimiquement lié à l'ingrédient actif, p.ex. conjugués polymère-médicament
The present invention relates to herbal extracts of Sinapis Semen, Corydalis Tuber, Pharbitidis Seed and Strychni Ignatii Semen, and a composition containing the same for treating and preventing gastrointestinal motility disorder. The extracts of the present invention have a remarkable effect of promoting gastrointestinal motility through HT3 receptor antagonism and/or HT4 receptor agonism.
brevets